These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 2864155)

  • 1. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
    Azadkhan AK; Truelove SC; Aronson JK
    Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa.
    Bondesen S; Tage-Jensen U; Jacobsen O; Hansen SH; Rasmussen SN; Hvidberg EF
    Eur J Clin Pharmacol; 1986; 31(1):23-6. PubMed ID: 2877884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
    Klotz U; Maier KE
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):46S-50S. PubMed ID: 3319458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of stress-induced gastric ulcers by sulphasalazine and its constituents (sulphapyridine and 5-aminosalicylic acid) in rats.
    Garg GP; Cho CH; Ogle CW
    Pharmacology; 1990; 40(6):318-24. PubMed ID: 1978355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
    Thomson AB
    Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the pK values of 5-aminosalicylic acid and N-acetylaminosalicylic acid and comparison of the pH dependent lipid-water partition coefficients of sulphasalazine and its metabolites.
    Allgayer H; Sonnenbichler J; Kruis W; Paumgartner G
    Arzneimittelforschung; 1985; 35(9):1457-9. PubMed ID: 2867770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.
    Shafii A; Chowdhury JR; Das KM
    Am J Gastroenterol; 1982 May; 77(5):297-9. PubMed ID: 6123257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1988 Jan; 23(1):107-12. PubMed ID: 2894070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
    Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
    Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
    Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
    Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
    Bird HA
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.
    Yamaguchi T; Sasaki K; Kurosaki Y; Nakayama T; Kimura T
    J Drug Target; 1994; 2(2):123-31. PubMed ID: 7915179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
    Willoughby CP; Aronson JK; Agback H; Bodin NO; Truelove SC
    Gut; 1982 Dec; 23(12):1081-7. PubMed ID: 7173720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.